Revolution Medicines, Inc. NASDAQ:RVMD

Revolution Medicines stock price today

$36.54
-7.67
-17.35%
Financial Health
0
1
2
3
4
5
6
7
8
9

Revolution Medicines stock price monthly change

-2.06%
month

Revolution Medicines stock price quarterly change

-2.06%
quarter

Revolution Medicines stock price yearly change

+50.84%
year

Revolution Medicines key metrics

Market Cap
7.91B
Enterprise value
1.58B
P/E
-6.85
EV/Sales
44.83
EV/EBITDA
-6.54
Price/Sales
47.58
Price/Book
2.45
PEG ratio
0.34
EPS
-3.75
Revenue
N/A
EBITDA
-550.02M
Income
-484.27M
Revenue Q/Q
-100%
Revenue Y/Y
-86.88%
Profit margin
-702.95%
Oper. margin
-730.01%
Gross margin
0%
EBIT margin
-730.01%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Revolution Medicines stock price history

Revolution Medicines stock forecast

Revolution Medicines financial statements

Average Price Target
Last Year

$63.86

Potential upside: 74.75%

Based on estimate of 5 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Revolution Medicines, Inc. (NASDAQ:RVMD): Profit margin
Jun 2023 3.82M -98.29M -2570.55%
Sep 2023 0 -108.43M
Dec 2023 742K -161.53M -21770.49%
Mar 2024 0 -116.00M
Revolution Medicines, Inc. (NASDAQ:RVMD): Debt to assets
Jun 2023 1073709000 142.87M 13.31%
Sep 2023 984232000 146.77M 14.91%
Dec 2023 2088591000 262.39M 12.56%
Mar 2024 1908362000 182.89M 9.58%
Revolution Medicines, Inc. (NASDAQ:RVMD): Cash Flow
Jun 2023 -67.12M -43.54M 64.63M
Sep 2023 -100.49M 77.35M 1.01M
Dec 2023 -120.56M -380.40M 839.35M
Mar 2024 -160.56M -247.96M 810K

Revolution Medicines alternative data

Revolution Medicines, Inc. (NASDAQ:RVMD): Employee count
Aug 2023 259
Sep 2023 292
Oct 2023 292
Nov 2023 292
Dec 2023 338
Jan 2024 338
Feb 2024 338
Mar 2024 378
Apr 2024 378
May 2024 378
Jun 2024 411
Jul 2024 411

Revolution Medicines other data

47.24% -52.76%
of RVMD is owned by hedge funds
38.08M -50.30M
shares is hold by hedge funds

Revolution Medicines, Inc. (NASDAQ:RVMD): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 18167
Mar 2024 0 38509
Apr 2024 0 19655
May 2024 0 11500
Jun 2024 0 55120
Jul 2024 0 56221
Aug 2024 0 26667
Sep 2024 0 41076
Oct 2024 0 132866
Nov 2024 0 95220
Dec 2024 1304347 24940
Transaction Date Insider Security Shares Price per share Total value Source
Option
GOLDSMITH MARK A director, officer.. Common Stock 30,846 $0.49 $15,115
Option
GOLDSMITH MARK A director, officer.. Stock Option (Right to Buy) 30,846 $0.49 $15,115
Sale
KELSEY STEPHEN MICHAEL officer: See Remarks
Common Stock 4,663 $45.4 $211,719
Sale
HORN MARGARET A officer: Chief Op.. Common Stock 4,329 $45.4 $196,554
Sale
GOLDSMITH MARK A director, officer.. Common Stock 11,714 $45.4 $531,862
Sale
CISLINI JEFF officer: General Counsel
Common Stock 1,599 $45.4 $72,601
Sale
ANDERS JACK officer: Chief Financial Officer
Common Stock 2,635 $45.4 $119,640
Purchase
SCHROEDER THILO director
Common Stock 543,478 $46 $24,999,988
Purchase
SCHROEDER THILO director
Common Stock 760,869 $46 $34,999,974
Sale
CISLINI JEFF officer: General Counsel
Common Stock 2,554 $55.13 $140,812
Patent
Application
Filling date: 11 Jun 2021 Issue date: 12 May 2022
Application
Filling date: 10 Jun 2021 Issue date: 12 May 2022
Application
Filling date: 2 Mar 2020 Issue date: 5 May 2022
Application
Filling date: 15 Sep 2021 Issue date: 7 Apr 2022
Application
Filling date: 21 Dec 2020 Issue date: 17 Mar 2022
Application
Filling date: 6 Apr 2021 Issue date: 3 Feb 2022
Grant
Filling date: 26 Feb 2021 Issue date: 11 Jan 2022
Application
Filling date: 28 Jan 2021 Issue date: 30 Dec 2021
Grant
Filling date: 23 Dec 2020 Issue date: 9 Nov 2021
Application
Filling date: 28 Oct 2020 Issue date: 4 Nov 2021
Insider Compensation
Dr. Mark A. Goldsmith Ph.D. (1962) Chief Executive Officer, Pres & Chairman $962,010
Dr. Stephen M. Kelsey M.D., FRCP, FRC Path. (1961) Pres of R&D
$739,910
Ms. Margaret A. Horn (1963) Chief Operating Officer, Gen. Counsel & Sec. $735,390
Sunday, 15 December 2024
247wallst.com
Thursday, 5 December 2024
globenewswire.com
Wednesday, 4 December 2024
seekingalpha.com
Tuesday, 3 December 2024
globenewswire.com
Monday, 2 December 2024
globenewswire.com
globenewswire.com
Wednesday, 27 November 2024
globenewswire.com
Wednesday, 6 November 2024
seekingalpha.com
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
Friday, 25 October 2024
globenewswire.com
Wednesday, 23 October 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Monday, 7 October 2024
globenewswire.com
Sunday, 11 August 2024
seekingalpha.com
Wednesday, 7 August 2024
globenewswire.com
Wednesday, 31 July 2024
globenewswire.com
Tuesday, 16 July 2024
benzinga.com
Thursday, 11 July 2024
globenewswire.com
Wednesday, 10 July 2024
zacks.com
Monday, 8 July 2024
globenewswire.com
prnewswire.com
Saturday, 8 June 2024
investorplace.com
Wednesday, 5 June 2024
globenewswire.com
Wednesday, 8 May 2024
globenewswire.com
Wednesday, 1 May 2024
GlobeNewsWire
Thursday, 4 April 2024
GlobeNewsWire
Monday, 26 February 2024
Zacks Investment Research
Tuesday, 20 February 2024
GlobeNewsWire
  • What's the price of Revolution Medicines stock today?

    One share of Revolution Medicines stock can currently be purchased for approximately $36.54.

  • When is Revolution Medicines's next earnings date?

    Unfortunately, Revolution Medicines's (RVMD) next earnings date is currently unknown.

  • Does Revolution Medicines pay dividends?

    No, Revolution Medicines does not pay dividends.

  • How much money does Revolution Medicines make?

    Revolution Medicines has a market capitalization of 7.91B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 67.27% to 11.58M US dollars.

  • What is Revolution Medicines's stock symbol?

    Revolution Medicines, Inc. is traded on the NASDAQ under the ticker symbol "RVMD".

  • What is Revolution Medicines's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Revolution Medicines?

    Shares of Revolution Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Revolution Medicines's key executives?

    Revolution Medicines's management team includes the following people:

    • Dr. Mark A. Goldsmith Ph.D. Chief Executive Officer, Pres & Chairman(age: 63, pay: $962,010)
    • Dr. Stephen M. Kelsey M.D., FRCP, FRC Path. Pres of R&D(age: 64, pay: $739,910)
    • Ms. Margaret A. Horn Chief Operating Officer, Gen. Counsel & Sec.(age: 62, pay: $735,390)
  • How many employees does Revolution Medicines have?

    As Jul 2024, Revolution Medicines employs 411 workers, which is 9% more then previous quarter.

  • When Revolution Medicines went public?

    Revolution Medicines, Inc. is publicly traded company for more then 5 years since IPO on 13 Feb 2020.

  • What is Revolution Medicines's official website?

    The official website for Revolution Medicines is revmed.com.

  • Where are Revolution Medicines's headquarters?

    Revolution Medicines is headquartered at 700 Saginaw Drive, Redwood City, CA.

  • How can i contact Revolution Medicines?

    Revolution Medicines's mailing address is 700 Saginaw Drive, Redwood City, CA and company can be reached via phone at +65 04816801.

  • What is Revolution Medicines stock forecast & price target?

    Based on 5 Wall Street analysts` predicted price targets for Revolution Medicines in the last 12 months, the avarage price target is $63.86. The average price target represents a 74.75% change from the last price of $36.54.

Revolution Medicines company profile:

Revolution Medicines, Inc.

revmed.com
Exchange:

NASDAQ

Full time employees:

490

Industry:

Biotechnology

Sector:

Healthcare

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

700 Saginaw Drive
Redwood City, CA 94063

CIK: 0001628171
ISIN: US76155X1000
CUSIP: 76155X100